HbG-Makassar Binding Polypeptides for Sickle Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for sickle cell disease lack specific reagents and products to accurately detect and identify the HbG-Makassar polypeptide, which is essential for managing the disease, due to cross-reactivity issues with other hemoglobin forms.
Innovation Solution
Development of binding polypeptides, such as antibodies or antigen binding portions, that specifically bind to the HbG-Makassar hemoglobin variant while minimizing interaction with wild-type beta-globin or sickle cell globin, utilizing specific complementarity determining regions (CDRs) to ensure precise identification in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If binding polypeptides are designed to detect HbG-Makassar, then detection accuracy improves, but cross-reactivity with other hemoglobin forms increases
Solution Approach 1:
The patent applies local quality by designing antibodies with specifically engineered complementarity determining regions (CDRs) that recognize unique epitopes on HbG-Makassar. The CDR sequences are optimized to bind locally to specific regions of the HbG-Makassar polypeptide that differ from other hemoglobin variants, thereby achieving high detection accuracy while minimizing cross-reactivity with wild-type beta-globin or sickle cell globin.
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequences of the CDR regions to alter the binding characteristics of the antibodies. By changing specific amino acid parameters in the CDR1, CDR2, and CDR3 regions, the antibodies achieve enhanced specificity for HbG-Makassar while reducing unwanted cross-reactivity with other hemoglobin forms.
2Reliability
If specific antibodies for HbG-Makassar are developed, then disease management accuracy improves, but reagent complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody structure into distinct functional components: variable regions (VH and VL) with specific CDR sequences for antigen recognition, and constant regions for structural stability. This segmentation allows for modular design where only the CDR regions need to be highly specific, while the framework regions can be standardized, thereby reducing overall reagent complexity while maintaining high reliability for disease management.
Solution Approach 2:
The patent employs universality by designing antibodies with standardized constant regions that can be used across different diagnostic applications. The multi-functional CDR sequences are engineered to recognize HbG-Makassar while the constant regions provide universal binding properties that simplify reagent preparation and usage, reducing complexity despite high specificity requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These binding polypeptides effectively identify HbG-Makassar polypeptide in samples, reducing false positives and enabling accurate monitoring and management of sickle cell disease by distinguishing it from other hemoglobin variants.
Implementation Method 1
binding polypeptides, such as antibodies, or antigen binding portions thereof, that specifically bind to the HbG-Makassar hemoglobin (Hb) polypeptide
Data Source
AI summary
Described and featured herein are binding polypeptides and antibodies, and antigen binding portions thereof, that specifically bind to the HbG-Makassar variant polypeptide or peptide and methods of using such binding polypeptides and antibodies to specifically bind, detect, identify, select, and/or isolate the HbG-Makassar variant polypeptide or peptide, for example, in a biological sample.